Document Detail


Is depressed myocyte contractility centrally involved in heart failure?
MedLine Citation:
PMID:  12623873     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This review examines the evidence for and against the hypothesis that abnormalities in cardiac contractility initiate the heart failure syndrome and drive its progression. There is substantial evidence that the contractility of failing human hearts is depressed and that abnormalities of basal Ca2+ regulation and adrenergic regulation of Ca2+ signaling are responsible. The cellular and molecular defects that cause depressed myocyte contractility are not well established but seem to culminate in abnormal sarcoplasmic reticulum uptake, storage, and release. There are also strong links between Ca2+ regulation, Ca2+ signaling pathways, hypertrophy, and heart failure that need to be more clearly delineated. There is not substantial direct evidence for a causative role for depressed contractility in the initiation and progression of human heart failure, and some studies show that heart failure can occur without depressed myocyte contractility. Stronger support for a causal role for depressed contractility in the initiation of heart failure comes from animal studies where maintaining or improving contractility can prevent heart failure. Recent clinical studies in humans also support the idea that beneficial heart failure treatments, such as beta-adrenergic antagonists, involve improved contractility. Current or previously used heart failure treatments that increase contractility, primarily by increasing cAMP, have generally increased mortality. Novel heart failure therapies that increase or maintain contractility or adrenergic signaling by selectively modulating specific molecules have produced promising results in animal experiments. How to reliably implement these potentially beneficial inotropic therapies in humans without introducing negative side effects is the major unanswered question in this field.
Authors:
Steven R Houser; Kenneth B Margulies
Related Documents :
15705143 - Clinical decision-making and myocardial viability: current perspectives.
24259703 - Acute ischemic stroke following cardioversion in a patient receiving dabigatran.
20517163 - Left ventricular diastolic function in patients on hemodialysis.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Circulation research     Volume:  92     ISSN:  1524-4571     ISO Abbreviation:  Circ. Res.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-07     Completed Date:  2003-03-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0047103     Medline TA:  Circ Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  350-8     Citation Subset:  IM    
Affiliation:
Cardiovascular Research Group, Temple University School of Medicine, 3400 N Broad St, Philadelphia, PA 19140, USA. srhouser@unix.temple.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Calcium / metabolism
Calcium Channel Blockers / pharmacology
Calcium Channels, L-Type / metabolism
Cyclic AMP / metabolism
Heart Failure / drug therapy,  metabolism,  physiopathology*
Humans
Myocardial Contraction / drug effects,  physiology
Myocytes, Cardiac / drug effects,  physiology*
Receptors, Adrenergic, beta / metabolism
Grant Support
ID/Acronym/Agency:
AG17022/AG/NIA NIH HHS; HL33921/HL/NHLBI NIH HHS; HL61495/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Calcium Channels, L-Type; 0/Receptors, Adrenergic, beta; 60-92-4/Cyclic AMP; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study.
Next Document:  Spatial microstimuli in endothelial mechanosignaling.